Live Breaking News & Updates on Gregoryp Cosgrove

Stay updated with breaking news from Gregoryp cosgrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pliant Therapeutics Presents Data From Its Bexotegrast Program At The American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and le ....

United States , Christopher Keenan , Gregoryp Cosgrove , Los Angeles , Jonathang Goldin , Martinl Decaris , European Medicines Agency , David Geffen School Of Medicine , Development For Idiopathic Pulmonary Fibrosis , Pliant Therapeutics Inc , University Of California , Translational Sciences At Pliant , Clinical Development At Pliant Therapeutics , Corporate Communications , American Thoracic Society , Drug Administration , International Conference , Chief Medical Officer , Dual Selective Inhibitor , Idiopathic Pulmonary Fibrosis , Primary Sclerosing Cholangitis , Vice President , Clinical Development , Pliant Therapeutics , Specific Cell Types , Fibrotic Human Lung ,

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2024 Pliant Therapeutics, Inc. , a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment. ....

United States , Jonathang Goldin , Martinl Decaris , Christopher Keenan , Los Angeles , Gregoryp Cosgrove , Drug Administration , American Thoracic Society , International Conference , Pliant Therapeutics Inc , European Medicines Agency , Corporate Communications , David Geffen School Of Medicine , Clinical Development At Pliant Therapeutics , Development For Idiopathic Pulmonary Fibrosis , University Of California , Translational Sciences At Pliant , Chief Medical Officer , Dual Selective Inhibitor , Idiopathic Pulmonary Fibrosis , Primary Sclerosing , Vice President , Clinical Development , Pliant Therapeutics , Specific Cell Types , Fibrotic Human ,

Pliant Therapeutics Presents Data from its Bexotegrast

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader. ....

United States , Jonathang Goldin , Los Angeles , Gregoryp Cosgrove , Christopher Keenan , Martinl Decaris , Drug Administration , David Geffen School Of Medicine , International Conference , Corporate Communications , American Thoracic Society , Translational Sciences At Pliant , Pliant Therapeutics Inc , University Of California , European Medicines Agency , Clinical Development At Pliant Therapeutics , Chief Medical Officer , Vice President , Clinical Development , Pliant Therapeutics , Principal Scientist , Senior Director , Translational Sciences , Biomedical Physics , David Geffen School , Fast Track Designation ,

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, takin ....

San Diego Convention Center , United States , San Diego , Martinl Decaris , Christopher Keenan , Gregoryp Cosgrove , Los Angeles , Jonathang Goldin , Clinical Development , Pliant Therapeutics Inc , International Conference , University Of California , European Medicines Agency , David Geffen School Of Medicine , Corporate Communications , American Thoracic Society , Drug Administration , Translational Sciences , Thoracic Society , Senior Director , Unveiling Novel Avenues , Principal Scientist , New Therapeutics Targets , Upper Level , Biomedical Physics , David Geffen School ,

Pulmonary Fibrosis Foundation Urges COVID-19 Vaccination In Letter To Patients

Press release content from PR Newswire. The AP news staff was not involved in its creation.
Pulmonary Fibrosis Foundation Urges COVID-19 Vaccination In Letter To Patients
December 28, 2020 GMT
The Pulmonary Fibrosis Foundation s Medical and Scientific Advisory Board is recommending COVID-19 vaccination for individuals with pulmonary fibrosis.
The Pulmonary Fibrosis Foundation s Medical and Scientific Advisory Board is recommending COVID-19 vaccination for individuals with pulmonary fibrosis.
CHICAGO, Dec. 28, 2020 /PRNewswire/ The Pulmonary Fibrosis Foundation (PFF) is encouraging COVID-19 vaccination for individuals with pulmonary fibrosis, a progressive and debilitating lung disease affecting more than 200,000 Americans.
In a letter to the PF community, the PFF Medical & Scientific Advisory Board strongly recommends vaccination, along with the safe practices of physical distancing, hand washing, and face coverings, to help prevent COVID-19 illness. ....

United States , Dorothy Coyle , Kevinr Flaherty , Joseph Lasky , Gregoryp Cosgrove , Williamt Schmidt , Better Business Bureau , Centers For Disease , Pulmonary Fibrosis Community , Steering Committee , National Health Council , Pulmonary Fibrosis Foundation Medical Scientific Advisory Board , Charity Navigator , Pulmonary Fibrosis Foundation , Scientific Advisory Board , Emergency Use Authorization , Disease Control , Pulmonary Fibrosis Foundation Medical , Medical Advisory , Scientific Advisory , New England , Advisory Committee , Immunization Practice Interim Recommendation , Allocating Initial Supplies , Mortal Wkly Rep , Pulmonary Fibrosis ,